MEI Pharma (MEIP) Competitors $2.60 -0.05 (-1.70%) Closing price 02/21/2025 03:50 PM EasternExtended Trading$2.75 +0.14 (+5.53%) As of 02/21/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MEIP vs. AVTE, PWUP, BLUE, FTLF, VTVT, BYSI, ME, HOWL, IPSC, and AADIShould you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Aerovate Therapeutics (AVTE), PowerUp Acquisition (PWUP), bluebird bio (BLUE), FitLife Brands (FTLF), vTv Therapeutics (VTVT), BeyondSpring (BYSI), 23andMe (ME), Werewolf Therapeutics (HOWL), Century Therapeutics (IPSC), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. MEI Pharma vs. Aerovate Therapeutics PowerUp Acquisition bluebird bio FitLife Brands vTv Therapeutics BeyondSpring 23andMe Werewolf Therapeutics Century Therapeutics Aadi Bioscience MEI Pharma (NASDAQ:MEIP) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Is MEIP or AVTE more profitable? MEI Pharma's return on equity of -84.92% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MEI PharmaN/A -84.92% -67.53% Aerovate Therapeutics N/A -90.19%-77.47% Do insiders and institutionals hold more shares of MEIP or AVTE? 52.4% of MEI Pharma shares are owned by institutional investors. 3.1% of MEI Pharma shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, MEIP or AVTE? MEI Pharma has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Does the media refer more to MEIP or AVTE? In the previous week, MEI Pharma and MEI Pharma both had 1 articles in the media. Aerovate Therapeutics' average media sentiment score of 1.95 beat MEI Pharma's score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MEI Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aerovate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer MEIP or AVTE? MEI Pharma presently has a consensus target price of $7.00, indicating a potential upside of 168.71%. Aerovate Therapeutics has a consensus target price of $2.25, indicating a potential downside of 5.06%. Given MEI Pharma's higher probable upside, equities analysts plainly believe MEI Pharma is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MEI Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, MEIP or AVTE? MEI Pharma has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMEI Pharma$65.30M0.27$17.78M-$5.73-0.45Aerovate TherapeuticsN/AN/A-$75.52M-$2.99-0.79 Does the MarketBeat Community prefer MEIP or AVTE? MEI Pharma received 393 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 62.71% of users gave MEI Pharma an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformMEI PharmaOutperform Votes41262.71% Underperform Votes24537.29% Aerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% SummaryMEI Pharma beats Aerovate Therapeutics on 9 of the 13 factors compared between the two stocks. Get MEI Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MEIP vs. The Competition Export to ExcelMetricMEI PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.66M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.455.4725.4719.00Price / Sales0.27306.08447.5876.30Price / Cash0.4465.6738.0134.83Price / Book0.786.717.644.62Net Income$17.78M$138.33M$3.18B$245.85M7 Day Performance-3.16%-2.61%-1.99%-2.68%1 Month Performance-5.96%-2.32%-0.42%-2.19%1 Year Performance-38.12%-5.31%16.51%12.84% MEI Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MEIPMEI Pharma4.1543 of 5 stars$2.61-1.7%$7.00+168.7%-41.1%$17.66M$65.30M-0.45100Analyst ForecastAVTEAerovate Therapeutics0.6156 of 5 stars$2.45-0.4%$2.25-8.2%-87.4%$70.74MN/A-0.8220Positive NewsPWUPPowerUp AcquisitionN/A$9.10-16.1%N/A-44.0%$70.71MN/A0.00N/ANews CoverageGap UpBLUEbluebird bio1.7446 of 5 stars$7.27+0.3%$49.14+576.0%-81.3%$70.66M$29.50M-0.19520Options VolumeNews CoverageGap DownFTLFFitLife Brands4.4549 of 5 stars$15.15+0.9%$20.00+32.0%+37.7%$69.84M$52.70M8.9620News CoverageVTVTvTv Therapeutics1.3709 of 5 stars$21.70+2.4%$35.00+61.3%+126.2%$69.22M$2.02M-4.799BYSIBeyondSpringN/A$1.75+2.9%N/A+52.6%$68.30M$1.75M0.0080News CoverageME23andMe1.3628 of 5 stars$2.55+3.2%$9.40+268.6%-81.9%$66.60M$208.78M-0.17770Analyst ForecastNews CoverageHOWLWerewolf Therapeutics2.1954 of 5 stars$1.49-1.3%$9.33+526.4%-79.2%$66.40M$3.39M-0.9740IPSCCentury Therapeutics2.387 of 5 stars$0.77+2.8%$10.00+1,191.2%-82.5%$65.86M$2.68M-0.42170AADIAadi Bioscience0.8007 of 5 stars$2.59-0.8%$1.67-35.6%+49.2%$63.97M$25.07M-1.1440 Related Companies and Tools Related Companies Aerovate Therapeutics Alternatives PowerUp Acquisition Alternatives bluebird bio Alternatives FitLife Brands Alternatives vTv Therapeutics Alternatives BeyondSpring Alternatives 23andMe Alternatives Werewolf Therapeutics Alternatives Century Therapeutics Alternatives Aadi Bioscience Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MEIP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MEIP Stock Alerts